New Covid Study: Convalescent Plasma Treatment Sees Promise

New Covid Study: Convalescent Plasma Treatment Sees Promise
SHARE

There are all kinds of viable treatments for the novel coronavirus-triggered disease, and today, we are addressing the one involving plasma. 

ABC News reported that the medical researchers say there is renewed promise in reducing covid-related hospitalizations and deaths by increasing the use of convalescent plasma treatments early on in a coronavirus infection.

More than that, it’s been revealed that the medical experts are pushing the federal government to allow more patients to receive the treatment.

This is happening as lab-based monoclonal treatments such as Regeneron have seen lessened effectiveness against the Omicron variant.

The Omicron covid variant 

The Omicron covid variant keeps making headlines these days.

Deseret online publication notes that the Omicron variant of the coronavirus continues to spread throughout the world. People have an idea of what Omicron symptoms look like for infected people.

“The ZOE COVID Study, which has analyzed thousands of COVID-19 cases and reported on symptoms of those cases, has revealed the top symptoms for people who were infected with the coronavirus at the time when the omicron variant likely started to spread,” according to CNBC.

Source: deadline.com

The symptoms really seem to be similar to other coronavirus variants. Check out the top five symptoms. 

Runny nose.
Headache.
Fatigue (either mild or severe).
Sneezing.
Sore throat.

Convalescent plasma study results are in

It’s been also revealed that the researchers at John Hopkins University on Tuesday released the results of a 16-month nationwide study on convalescent plasma use on covid patients.

The main thing worth noting is that they found it had a 54% relative risk reduction in covid-related hospitalizations.

According to the same online publication mentioned at the beginning of this article Dr. Arturo Casadevall, one of the study’s co-authors and chair of the department of molecular microbiology and immunology at Johns Hopkins Bloomberg School of Public Health, told ABC News that the results are promising.

The results show great signs especially if the plasma is used early on in the infection period.

“The results show a 54% efficacy in reducing hospitalization if you give it up to day nine. It is clear and highly significant,” he said.

He continued and said this:

“If you look to less than five days, the efficacy is much, much higher.”

Make sure to stay safe, you and your loved ones. 


SHARE
Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.